NovoCure Ltd. (NVCR)

NovoCure's stock price has experienced significant volatility over the past six months. The 52-week range for NVCR stock has been between $9.82 and $23.18. As of early February 2026, the stock price was around $10.13, representing a decline of approximately 49.98% from its price in February 2025. Key events impacting the stock price include the announcement of preliminary Q4 and full year 2025 performance, reporting record annual revenue for 2025. The Centers for Medicare & Medicaid Services (CMS) revoked its billing privileges for the company's product, projecting a roughly $13 million monthly revenue impact, leading to a decline in NVCR shares. The company presented at the 44th Annual J.P. Morgan Healthcare Conference in January 2026. Analysts have maintained a mixed outlook, citing the company's innovative technology and pipeline potential against ongoing financial challenges.

Based on the available information, there is no explicit mention or indication of demand seasonality for NovoCure Ltd.'s products and services. The demand for cancer treatments is generally driven by disease incidence and progression rather than seasonal factors.

NovoCure Ltd. is an oncology company focused on developing, manufacturing, and commercializing its proprietary Tumor Treating Fields (TTFields) technology. The company operates within the healthcare sector, specifically in the drug discovery, medical devices, and biotechnology industries. NovoCure's core business involves the use of electric fields tuned to specific frequencies to disrupt the division of solid tumor cancer cells. Its major commercialized products include Optune Gio and Optune Lua, which are TTFields delivery systems approved in certain countries for the treatment of adult patients with glioblastoma, non-small cell lung cancer, and malignant pleural mesothelioma. NovoCure also has a robust pipeline of products and technologies under investigation, including Trident, Lunar-2, Panova-3, and Metis, for the treatment of various cancers such as glioblastoma, non-small cell lung cancer, and pancreatic cancer.

NovoCure Ltd. has a global geographic footprint, deriving the majority of its revenue from the United States. The company also has significant operations and revenue streams from Germany, Japan, France, and other international markets. Its strategic partnership with Zai Lab facilitates market access in Greater China. NovoCure's corporate office is located in Baar, Switzerland.

NovoCure's brand reputation is centered around its innovative Tumor Treating Fields (TTFields) therapy. The company is recognized for its pioneering approach to non-invasive cancer treatment, with positive sentiment stemming from ongoing clinical trials and FDA approvals. However, the company has faced challenges in translating regulatory approvals into widespread market adoption and revenue growth. The recent revocation of CMS billing privileges could negatively affect its reputation, although some analysts view it as a temporary administrative setback. The company's commitment to its "Patient Forward" culture and direct patient support contributes positively to its reputation among patients and caregivers.

NovoCure Limited has a significant institutional ownership, with 395 institutional owners and shareholders holding a total of 104,611,358 shares, accounting for approximately 75.4% of the company. Major institutional owners include FMR LLC, BlackRock, Inc., The Vanguard Group, Inc., Soleus Capital Management, L.P., State Street Corp, and Geode Capital Management, Llc. Individual ownership accounts for approximately 10% of the company, with Hansjörg Wyss noted as a significant individual owner.